Anti-NOTCH2&3 therapeutic antibody (Pre-made Tarextumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-551-1mg	1mg	3090
GMP-Bios-ab-551-10mg	10mg	21890
GMP-Bios-ab-551-100mg	100mg	148000
GMP-Bios-ab-551-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-NOTCH2&3 therapeutic antibody (Pre-made Tarextumab biosimilar,Whole mAb)
INN Name	Tarextumab
Target	NOTCH2&3
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	OncoMed Pharmaceuticals
Conditions Approved	na
Conditions Active	Pancreatic cancer;Small cell lung cancer
Conditions Discontinued	Solid tumours
Development Tech	MorphoSys HuCAL Phage Display;XmAb Engineering Technology